Regulatory compliance - April 30, 2015
Drs. Resign Amid AZ Payment Probe
Two psychiatrists with Terrell State Hospital (TSH) in Texas, U.S., resigned after allegedly receiving hundreds of thousands of dollars from AstraZeneca, according to the Texas Department of State Health Services. Allegedly the two physicians violated several department rules related to their relationship with AstraZeneca and efforts to have the antipsychotic medication Seroquel XR placed on […]
Collaboration - April 29, 2015
AZ, Celgene Tackle Blood Cancer
AstraZeneca has entered into a $450 million agreement with Celgene that will permit the U.S.-based drug firm to develop MEDI4736, AstraZeneca’s immunotherapy treatment for blood cancer. The agreement sent Celgene’s stock surging. AstraZeneca officials say the deal is a way to get the drug to market faster, according to Reuters. Blood cancer treatments eventually will […]
Profiles in Business - April 28, 2015
Remaining at the forefront
Jan-Olof Jacke, AstraZeneca AB’s new CEO, on maintaining the company’s position in Sweden. Keeping AstraZeneca AB in the forefront – as a research and marketing leader, a key component of Sweden’s domestic economy and export business and as a contributor to AstraZeneca’s overall growth – are priorities that AstraZeneca AB’s CEO Jan-Olof Jacke brings to […]
Collaboration - April 27, 2015
Juno, AZ Testing Cancer Remedy
Juno Therapeutics and AstraZeneca are joining forces to test their respective cancer treatments, combining new therapies designed to use the body’s immune system to combat tumors. Under the deal, the pair plans to jointly fund a Phase I study combining one of Juno’s CAR-T therapies and pair it with a promising antibody developed by MedImmune, […]
Collaboration - April 24, 2015
AZ, Amgen Switch to Psoriasis
Amgen and partner AstraZeneca are preparing to deliver U.S. and European applications for their plaque psoriasis drug brodalumab by midyear. The two companies halted tests for brodalumab as an asthma medication. Amgen outlined the news in its quarterly report, which also notes a 14 percent drop in R&D spending. “Based on the recommendation of an […]
New Market - April 3, 2015
AZ Drug on Swedish Market
AstraZeneca Pharmaceutical’s naloxegol or Moventig, is now available on the Swedish market, the first country in Europe since approval for the European market was granted in 2014. In mid- September 2014, naloxgel was approved for use in the U.S. under the name Movantik. It was launched on the US market this week. Naloxegol is intended […]
